MarketCap
Facebook
X
Telegram
NGM Biopharmaceuticals EV/EBITDA Ratio | NGM
Annual EV/EBITDA Ratio NGM Biopharmaceuticals
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.613 | -2.15 | -11.2 | -20.3 | -17.6 | 0.854 | -31.3 | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 0.854 | -31.3 | -11.8 |
EV/EBITDA Ratio of other stocks in the Biotechnology industry
| Issuer | EV/EBITDA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Repare Therapeutics
RPTX
|
0.101 | - | - | $ 112 M |  Canada |
 |
Sesen Bio
SESN
|
-1.13 | - | 7.29 % | $ 127 M |  USA |
 |
Windtree Therapeutics
WINT
|
-3.12 | - | - | $ 26.8 M | USA |
 |
Trean Insurance Group
TIG
|
1.79 K | - | - | $ 316 M | USA |
 |
SQZ Biotechnologies Company
SQZ
|
0.05 | - | 57.95 % | $ 12.8 M | USA |
 |
MEI Pharma
MEIP
|
0.0696 | - | 10.43 % | $ 20.5 M | USA |
 |
Palatin Technologies
PTN
|
0.657 | - | - | $ 13 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
14 | - | - | - |  Russia |
 |
Lyra Therapeutics
LYRA
|
-1.01 | - | - | $ 24.9 M | USA |
 |
Brickell Biotech
BBI
|
-0.0814 | - | -5.38 % | $ 6.06 M | USA |
 |
Applied Therapeutics
APLT
|
0.477 | - | - | $ 8.42 M | USA |
 |
ESSA Pharma
EPIX
|
-24.2 | - | - | $ 8.86 M | Canada |
 |
Generation Bio Co.
GBIO
|
-0.5 | - | - | $ 344 M | USA |
 |
Clearside Biomedical
CLSD
|
-1.5 | - | - | $ 25.3 M | USA |
 |
Merus N.V.
MRUS
|
-10.5 | - | - | $ 5.78 B |  Niderland |
 |
RAPT Therapeutics
RAPT
|
0.534 | - | - | $ 2.36 B | USA |
 |
Annexon
ANNX
|
-3.14 | $ 4.2 | -0.71 % | $ 651 M | USA |
 |
AbbVie
ABBV
|
24.9 | $ 293.87 | 0.19 % | $ 520 B | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
77.8 | $ 151.6 | -3.2 % | $ 19.9 B | USA |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
-41 | $ 4.63 | 21.05 % | $ 20 M |  Israel |
 |
Avenue Therapeutics
ATXI
|
0.57 | - | -52.27 % | $ 4.45 M | USA |
 |
Axon Enterprise
AXON
|
1.57 K | $ 302.6 | -0.19 % | $ 23.6 B | USA |
 |
Theratechnologies
THTX
|
17 | - | - | $ 83.9 M | Canada |
 |
Liquidia Corporation
LQDA
|
-61 | $ 51.37 | 7.31 % | $ 4.42 B | USA |
 |
CRISPR Therapeutics AG
CRSP
|
-6.79 | $ 45.05 | -9.97 % | $ 4.05 B |  Schweiz |
 |
Scholar Rock Holding Corporation
SRRK
|
-12.8 | $ 48.48 | -5.96 % | $ 5.56 B | USA |
 |
Geron Corporation
GERN
|
-19.5 | $ 0.96 | -3.71 % | $ 640 M | USA |
 |
Bristol-Myers Squibb Company
BMY
|
45.8 | $ 62.8 | 1.06 % | $ 128 B | USA |
 |
Titan Pharmaceuticals
TTNP
|
0.516 | - | -3.76 % | $ 3.47 M | USA |
 |
Kazia Therapeutics Limited
KZIA
|
-1.24 | $ 7.4 | -0.13 % | $ 113 M |  Australia |
 |
Celldex Therapeutics
CLDX
|
-7.28 | $ 30.68 | -1.81 % | $ 2.04 B | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
-0.355 | $ 4.0 | -6.76 % | $ 48.8 M | Israel |
 |
Allena Pharmaceuticals
ALNA
|
-1.22 | - | 3.16 % | $ 1.9 M | USA |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
31.2 | $ 317.26 | 0.99 % | $ 6.14 B | USA |
 |
Eli Lilly and Company
LLY
|
467 | $ 1 432.7 | 1.47 % | $ 1.29 T | USA |
 |
TCR2 Therapeutics
TCRR
|
-0.615 | - | - | $ 58.1 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
-8.07 | $ 84.95 | 0.13 % | $ 7.99 B | USA |
|
TFF Pharmaceuticals
TFFP
|
-0.366 | - | -60.05 % | $ 125 K | USA |
 |
Mesoblast Limited
MESO
|
-19.7 | $ 14.0 | -3.06 % | $ 16.9 B | Australia |
 |
CorMedix
CRMD
|
1.83 | $ 5.37 | -2.1 % | $ 387 K | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
-2.47 | - | -15.15 % | $ 60.3 M |  Britain |
 |
MannKind Corporation
MNKD
|
34.4 | $ 4.22 | 0.84 % | $ 1.29 B | USA |
 |
AVEO Pharmaceuticals
AVEO
|
-18.2 | - | - | $ 521 M | USA |
 |
MediciNova
MNOV
|
-3.2 | $ 1.4 | -4.76 % | $ 68.7 M | USA |
 |
Merck & Co.
MRK
|
97.3 | $ 147.75 | -0.68 % | $ 370 B | USA |
 |
Moderna
MRNA
|
-7.16 | $ 250.79 | -6.77 % | $ 97.6 B | USA |
 |
Axcella Health
AXLA
|
-0.295 | - | -16.42 % | $ 249 M | USA |